Recent Updates
Recently added Catalysts

HFA-152A propellant

Phase 1

Asthma | Small molecule | Respiratory |GSK plc|Last Updated: Aug 26, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDBiomarker
Total Trials1
Total Enrollment20
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06702462A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild AsthmaPHASE1 COMPLETED 20Mar 11, 2025Jun 4, 2025Aug 26, 20253 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage change from baseline in Forced expiratory volume in 1 second (FEV1) at 15 minutes
Baseline (0 minutes) and at 15 minutes post dose
Secondary Endpoints
Area under the forced expiratory volume in 1 second-time curve from zero to 15 minutes (FEV1 AUC0-15min)
Up to 15 minutes post dose
Percentage change from baseline in FEV1 at 5, 60 and 180 minutes
Baseline (0 minutes) and at 5, 60 and 180 minutes post dose
Percentage change from baseline in FEV1 <-15% at timepoints 5, 15, 60 and 180 minutes
Baseline (0 minutes) and at 5, 15, 60 and 180 minutes post dose
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
HFA-152A propellant followed by HFA-134A propellantEXPERIMENTAL -
HFA-134A propellant followed by HFA-152A propellantEXPERIMENTAL -
Interventions
NameTypeDescription
HFA-152A propellantDRUGHFA-152A propellant is administered via oral inhalation
HFA-134A propellantDRUGHFA-134A propellant is administered via oral inhalation
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: Participants are eligible to be included in the study if all the following criteria apply: * Male or female; females may be of childbearing potential, of nonchildbearing potential, or postmenopausal. * Participant must be 18 to 45 years of age inclusive, at the time of screenin...

Countries:United States
Unlock Eligibility Criteria